Late DES thrombosis: A lot of smoke, very little fire?

Catheterization and Cardiovascular Interventions

Volumn 69, Issue 4, 2007, Pages 609-615

  Fischell, Tim A ^a   Holmes, David R ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

Complications adult cath intervention; Restenosis; Thrombosis

Indexed keywords

HEPARIN; METAL; PACLITAXEL; RAPAMYCIN;

ANGIOCARDIOGRAPHY; ATHEROSCLEROTIC PLAQUE; BIOCOMPATIBILITY; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DISEASE COURSE; DRUG ELUTING STENT; HEART CATHETERIZATION; HEART MUSCLE REVASCULARIZATION; HUMAN; MEDICAL TECHNOLOGY; META ANALYSIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

CARDIOVASCULAR AGENTS; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; CORONARY THROMBOSIS; HUMANS; METALS; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; STENTS; TIME FACTORS;

EID: 33847642856     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21076     Document Type: Review

References (36)

1. Virmani R. The downside of drug-eluting stents. ACCEL interview with Lawrence Bonchek. September 2003.
2. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al for the BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. An observational study of drug-eluting versus bare-metal stents. Am College Cardiol 2006;48:2584-2591.
3. Camenzind E. Safety of drug-eluting stents: A meta-analysis of 1st generation DES programs. Oral Presentation at World Cardiology Congress 2006, Barcelona, Spain, 2006.
4. Conti R. Drug-eluting-stents-Safety concerns. Clin Cardiol 2006;29:479-180.
5. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: A meta-analysis. Eur Heart J 2006;27:2784-2814.
6. Morice M-C, Serruys PW, Sousa E, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
7. Moses JW, Leon MD, Popma JJ, Fitzerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, for the SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
8. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME, for the TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. Circulation 2004;109:1942-1947.
9. CYPHER® stent: Evaluation of benefits and risks. Available at www.cordis.com/active/crdus/en_US/html/cordis/downloads/155_5056_1_ARC_Overview. pdf
10. Cutlip DE. Stent thrombosis after drug-eluting stenting: Impact of a new standard definition on clinical trial results. Available at www.tctmd.com/ csportal/appmanager/tctmd/tct2006?_nfpb=true&_pageLabel=TCT2006Content& hdCon=1462891&srcId=1&destId=78 (Accessed November 14, 2006).
11. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
12. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent trials. Circulation 2001;106:1753-1755.
13. Cheneau E, Leborne L, Mintz GS, et al. Predictors of subacute stent thrombosis: Results of a systematic ultrasound study. Circulation 2003;108:43-47.
14. Fujii K, Carlier SG, Mintz GS, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation. J Am Coll Cardiol 2005;45:995-998.
15. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-278.
16. Wenaweser P. Late coronary stent thrombosis of DES in routine clinical practice. Oral Presentation at the World Cardiology Congress 2006. Barcelona, Spain, 2006.
17. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 2001;104:539-543.
18. Gupta V, Aravamuthan BR, Baskerville S, Smith SK, Gupta V, Lauer MA, Fischell TA. Reduction of subacute stent thrombosis (SAT) using heparin-coated stents in a large-scale, "real world" registry. J Invasive Cardiol 2004;16:304-310.
19. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-1124.
20. Wang F, Stouffer GA, Waxman S, Uretsky BF. Late coronary stent thrombosis: Early vs. late stent thrombosis in the stent era. Catheter Cardiovasc Interv 2002;55:142-147.
21. Heller L, Shemwell KC, Hug K. Late stent thrombosis in the absence of prior brachytherapy. Catheter Cardiovasc Interv 2001;53:23-28.
22. Wenaweser P, Rey C, Eberli FR, Togni M, Tüller D, Locher S, Remondino A, Seiler C, Hess OM, Meier B, Windecker S. Stent thrombosis following bare-metal stent implantation: Success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 2005;26:1180-1187.
23. Serruys PW, Ong AT, Morice MC, De Bruyne B, et al. Arterial revascularization therapies study. II. Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. EuroInterv 2005:147-156.
24. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis. Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-959.
25. Williams DO, Abbott D, Kip KE, for the DEScover Investigators. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents. Report of the DEScover registry. Circulation 2006;114:2154-2162.
26. Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice. One-year follow-up of the e-Cypher registry. Circulation 2006;113:1434-1441.
27. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign entity. Am Heart J 2006;151:1260-1264.
28. Pocock S, Bassand JP, Faxon D, Gersh B, Monro J, Turina M. Summary comments on pooled analysis of the TAXUS trials long term follow-up data. From the Global TAXUS Data Monitoring Committee, October 23, 2006.
29. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, Togni M, Billinger M, Tuller D, Seiler C, Roffi M, Corti R, Sutsch G, Maier W, Luscher T, Hess OM, Egger M, Meier B. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-662.
30. Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schömig A, Kastrati A. Vessel size and outcome after coronary drug-eluting stent placement: Results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. N Engl J Med 2006;48:1304-1309.
31. Kim YH, Park SW, Lee SW, Park DQ, Yun SC, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ, for the Long DES-II Study Investigators. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 2006;114:2148-2153.
32. Morice MC, Colombo A, Meier B, Serruys P, et al. for the REALITY Trial Investigators. Sirolimus- vs. paclitaxel-eluting stents in de novo coronary artery lesions: The REALITY trial: A randomized controlled trial. JAMA 2006;295:895-904.
33. Desai N, Cohen EA, Naylor D, et al. A randomized comparison of radial artery and saphenous-vein coronary bypass grafts. N Engl J Med 2004;22:2302-2309.
34. Widimsky P, Straka Z, Stros P, Jirasek K, et al. One-year coronary bypass graft patency: A randomized comparison between off-pump and on-pump surgery angiographic results of the PRAGUE-4 Trial. Circulation 2004;110:3418-3423.
35. PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery-PREVENT IV: A randomized controlled trial. JAMA 2005;294:2446-2454.
36. Newman MF, Kirchner JL, Phillips-Bute B, et al. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med 2001;344:395-402.